Fibrinolytic Therapy in Patients with Acute ST-elevation Myocardial Infarction.
Fibrinolytic Therapy in Patients with Acute ST-elevation Myocardial Infarction.
复制标题
DOI：
10.1016/j.iccl.2021.03.011
复制
发表时间：
2021-07-01
影响因子：
--
通讯作者：
Jneid, Hani
中科院分区：
文献类型：
--
作者：
Krittanawong, Chayakrit;Hahn, Joshua;Jneid, Hani
纤溶药物为ST段抬高心肌梗死(STEMI)患者提供了一种重要的替代治疗策略。最终，直接经皮冠状动脉介入治疗是大多数STEMI患者的首选再灌注策略，包括老年患者和冠状病毒病2019(新冠肺炎)感染患者。当初次介入治疗不能及时恰当地实施时，应始终考虑纤溶治疗。临床医生应及时发现纤溶治疗失败的迹象，并考虑抢救经皮冠状动脉介入治疗。当使用纤溶药物时，不应在使用纤溶药物后的最初3小时内进行冠状动脉造影术和血运重建。
Fibrinolytic agents provide an important alternative therapeutic strategy in individuals presenting with ST-elevation myocardial infarction (STEMI). Ultimately, primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for most patients with STEMI, including elderly patients and patients with coronavirus disease 2019 (COVID-19) infection. Fibrinolytic therapy should always be considered when timely primary PCI cannot be delivered appropriately. Clinicians should promptly recognize the signs of fibrinolytic therapy failure and consider rescue PCI. When fibrinolytics are used, coronary angiography and revascularization should not be conducted within the initial 3hours after fibrinolytic administration.